Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Xeris Biopharma (Nasdaq: XERS) announced that its CEO, Paul R. Edick, will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 12:00pm Eastern Time. The event will include a fireside chat format and will be accessible via a live webcast on the company's investor relations website. Xeris is focused on developing unique therapies in endocrinology, neurology, and gastroenterology, with products like Gvoke® for severe hypoglycemia and Recorlev® for Cushing’s syndrome, among others.

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and CEO of Xeris Biopharma, will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00pm Eastern Time. A live webcast of the fireside chat will be available on the investor relations section of the Company's website at www.xerispharma.com.

About Xeris Biopharma

Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient population in endocrinology, neurology, and gastroenterology. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005146/en/

Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

Source: Xeris Biopharma Holdings

FAQ

What event will Paul R. Edick participate in for Xeris Biopharma?

Paul R. Edick will participate in the 11th Annual SVB Leerink Global Healthcare Conference.

When is the SVB Leerink Global Healthcare Conference?

The conference is scheduled for February 16, 2022.

What time will the fireside chat take place?

The fireside chat will take place at 12:00pm Eastern Time.

Where can I watch the live webcast of the fireside chat?

The live webcast will be available on Xeris Biopharma's investor relations website.

What are some products developed by Xeris Biopharma?

Xeris Biopharma develops products like Gvoke® for severe hypoglycemia and Recorlev® for Cushing’s syndrome.